Analysis Group Study on Alzheimer's Disease Featured in Politico

August 8, 2016

An Analysis Group study related to Alzheimer's disease (AD) has been featured in a sponsored content article appearing in Politico. The article, "Alzheimer's science is changing, can policy catch up?" describes, in part, recent efforts to improve early diagnosis and treatment of Alzheimer's. The article references the findings of an Analysis Group study, "Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease: Evidence from the National Alzheimer's Coordinating Center Data," co-authored with Eli Lilly and recently presented as a poster at the 2016 Alzheimer's Association International Conference in Toronto in July. The Politico article cites the study's findings regarding the timing of a clinical diagnosis of AD relative to the initial onset of symptoms. 

The Analysis Group study compares demographic and clinical characteristics at the time of a subject's initial visit to an Alzheimer's Disease Center by time elapsed from first onset of cognitive symptoms, as well as downstream cognitive, functional, and treatment outcomes of patients diagnosed with probable AD. Earlier diagnosis of probable AD is associated with higher cognitive function, greater independence, and lower functional impairment at diagnosis. The findings suggest that as future therapies become available, earlier-diagnosed patients could be treated while cognitive and functional abilities are greater, potentially increasing patient benefit.

The study is co-authored by an Analysis Group team including Analysis Group Vice President Noam Y. Kirson and Principal Howard G. Birnbaum, in collaboration with Eli Lilly.

Read the Politico article